These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


203 related items for PubMed ID: 12742411

  • 1. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.
    Gao SZ, Chaparro SV, Perlroth M, Montoya JG, Miller JL, DiMiceli S, Hastie T, Oyer PE, Schroeder J.
    J Heart Lung Transplant; 2003 May; 22(5):505-14. PubMed ID: 12742411
    [Abstract] [Full Text] [Related]

  • 2. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [Abstract] [Full Text] [Related]

  • 4. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 5. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF.
    J Pediatr; 1997 Jul 27; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [Abstract] [Full Text] [Related]

  • 6. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber MI.
    Transplantation; 1997 Sep 27; 64(6):848-52. PubMed ID: 9326409
    [Abstract] [Full Text] [Related]

  • 7. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.
    J Pediatr Gastroenterol Nutr; 2004 Feb 27; 38(2):198-203. PubMed ID: 14734884
    [Abstract] [Full Text] [Related]

  • 8. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 9. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 15; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 10. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 11. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients.
    Boyle GJ, Michaels MG, Webber SA, Knisely AS, Kurland G, Cipriani LA, Griffith BP, Fricker FJ.
    J Pediatr; 1997 Aug 27; 131(2):309-13. PubMed ID: 9290623
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
    Kumarasinghe G, Lavee O, Parker A, Nivison-Smith I, Milliken S, Dodds A, Joseph J, Fay K, Ma DD, Malouf M, Plit M, Havryk A, Keogh AM, Hayward CS, Kotlyar E, Jabbour A, Glanville AR, Macdonald PS, Moore JJ.
    J Heart Lung Transplant; 2015 Nov 27; 34(11):1406-14. PubMed ID: 26279197
    [Abstract] [Full Text] [Related]

  • 13. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG, Tan MYQ, Quak SH, Aw MM.
    Transpl Infect Dis; 2018 Feb 27; 20(1):. PubMed ID: 29071779
    [Abstract] [Full Text] [Related]

  • 14. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL.
    Clin Transplant; 1995 Feb 27; 9(1):53-9. PubMed ID: 7742583
    [Abstract] [Full Text] [Related]

  • 15. Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation.
    Kim IC, Kim SH, Youn JC, Kim D, Lee S, Kim H, Kim JJ, Jung MH, Rossano JW, Cherikh WS, Kobashigawa JA, Stehlik J.
    JACC Heart Fail; 2024 Feb 27; 12(2):395-405. PubMed ID: 38326002
    [Abstract] [Full Text] [Related]

  • 16. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.
    Transplantation; 2000 Jul 15; 70(1):94-9. PubMed ID: 10919581
    [Abstract] [Full Text] [Related]

  • 17. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD, Hsu DT, Kichuk MR, Garvin JH, Stolar CJ, Haddad J, Stylianos S, Michler RE, Chadburn A, Knowles DM, Addonizio LJ.
    J Heart Lung Transplant; 1998 Dec 15; 17(12):1161-6. PubMed ID: 9883755
    [Abstract] [Full Text] [Related]

  • 18. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.
    Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL.
    J Infect Dis; 1992 Nov 15; 166(5):986-94. PubMed ID: 1328412
    [Abstract] [Full Text] [Related]

  • 19. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
    Muchtar E, Kramer MR, Vidal L, Ram R, Gurion R, Rosenblat Y, Bakal I, Shpilberg O.
    Transplantation; 2013 Oct 15; 96(7):657-63. PubMed ID: 23823652
    [Abstract] [Full Text] [Related]

  • 20. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.